Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bionomics ( (BNOX) ) has issued an update.
Neuphoria Therapeutics Inc. has completed its redomiciliation, transferring governance from Bionomics’ organizational documents to Neuphoria’s new Certificate of Incorporation and bylaws. This strategic move positions Neuphoria as the successor issuer to Bionomics, with its shares now registered under the Exchange Act, which may influence its governance structure and shareholder rights.
More about Bionomics
YTD Price Performance: -83.65%
Average Trading Volume: 9,738,552
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.72M
Find detailed analytics on BNOX stock on TipRanks’ Stock Analysis page.
